The Latest Cardiac and Vascular News
ENGLEWOOD, Colo., Feb. 25, 2021 /PRNewswire/ — 2020 Full Year Revenue increased 76% year over year to $80.1 million Orders increased 96% Net income of $9.1 million; Diluted EPS $0.26 Adjusted EBITDA $13.7 millio 2020 Revenue and Adjusted EBITDA are the highest in Company history 2020 Fourth Quarter Revenue increased 81% year over year to $25.6 million Orders […]
SAN FRANCISCO, Feb. 25, 2021 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today reported financial results for the three months and full year ended December 31, 2020. Fourth Quarter 2020 Financial Highlights Revenue of $78.8 million […]
Company Plans to Meet with FDA in Q1 to Discuss Results of GALACTIC-HF Enrollment Completed in Cohort 2 of REDWOOD-HCM; Results Expected Mid-Year Company Provides 2021 Financial Guidance; More Than Two Years of Cash Runway SOUTH SAN FRANCISCO, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) reported […]
Company demonstrates resilience despite COVID-19 challenges: Financial situation secure and development programs progressing Conference call begins today at 4:30 p.m. (ET) BASKING RIDGE, N.J., Feb. 25, 2021 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies […]
– Updates from ongoing PULSAR and SPECTRA Phase 2 clinical trials of sotatercept in patients with pulmonary arterial hypertension (PAH) presented at the American Heart Association (AHA) 2020 Scientific Sessions – – STELLAR Phase 3 trial initiated with sotatercept in PAH – – Acceleron recognized approximately $23.0 million in royalty […]
Fourth quarter 2020 revenues of $711.2 million, up 4.4% versus prior year period on an as-reported basis; up 2.3% on a constant currency basis Fourth quarter 2020 GAAP diluted EPS from continuing operations of $1.62, compared to $2.28 in the prior year period Fourth quarter 2020 adjusted diluted EPS from continuing […]
Q4 2020 reported revenue of $258.0 million, approximately equal to Q4 2019 revenue Q4 2020 core revenue on a constant currency basis* down (1.0)% compared to Q4 2019 Q4 2020 GAAP EPS of $0.27, compared to GAAP loss per share of ($0.08) in Q4 2019 Q4 2020 non-GAAP EPS* of […]
ST. LOUIS, Feb. 25, 2021 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the fourth quarter and full year ended December 31, 2020. “2020 was a year of significant progress despite a challenging macro environment,” said […]
VANCOUVER and MINNEAPOLIS, Feb. 24, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), has received written notification (the “Nasdaq Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with the minimum market value requirement set forth in the rules for […]
Record Revenue of $614.1 Million and $167.3 Million for Full Year and Fourth Quarter 2020 Despite COVID-19 Impact Received Positive CHMP Opinion for VAZKEPA® in Europe and Continue to Advance Commercial Launch Plans for Europe Management to Host Conference Call Today at 7:30 a.m. ET DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. […]
